ReviewMicroorganisms2024
Bacterial Vaginosis and Vulvovaginal Candidiasis Pathophysiologic Interrelationship.
Review in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Tinidazole vs metronidazole for the treatment of bacterial vaginosis: a systematic review and meta-analysis.Archives of gynecology and obstetrics · 2025Pooled it
- Impact of vaginal microbiota on the clinical efficacy and long-term recurrence of ketoconazole suppositories in treating severe vulvovaginal candidiasis: a secondary analysis of a multicentre randomised trial.Frontiers in cellular and infection microbiology · 2025Trial
- Longitudinal Clinical and Microscopic Findings After Dequalinium Chloride Treatment in Vulvovaginal Infections: A Retrospective Real-World Study from Mexican Gynecological Practice.Journal of clinical medicine · 2026Article
- Differential Virulence of VaginalJournal of fungi (Basel, Switzerland) · 2026Article
- Cytokine signalling in vaginal epithelial cells: mechanistic insights into epithelial immunity and inflammatory milieu in vulvovaginal candidiasis.European cytokine network · 2026Review
- The Gut-Vagina Axis.Microorganisms · 2026Review
- State-of-the-Art Review: Managing Vulvovaginal Candidiasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Elevated vaginal heparan sulfate correlates with impaired neutrophil killing ofInfection and immunity · 2026Article
- Clinical and Molecular Diagnostic Profiling of Vaginitis Using Multiplex Real-Time PCR: A Multicenter Study.Diagnostics (Basel, Switzerland) · 2026Article
- Regulatory Effects ofMicroorganisms · 2026Article
- Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents.Journal of fungi (Basel, Switzerland) · 2026Review
- Efficacy and Safety of Oteseconazole in Severe Vulvovaginal Candidiasis Categorized byDrug design, development and therapy · 2026Observational
- What is the impact of the virome and mycobiome on female reproductive tract health? A systematic scoping review.Frontiers in immunology · 2026Article
- Volatile organic compound profiling by HS-GC-IMS for vaginal infection identification.Frontiers in cellular and infection microbiology · 2026Article
- Advances in vulvovaginal candidiasis research: a comprehensive review from epidemiology, diagnosis, treatment to resistance mechanisms.Frontiers in microbiology · 2026Review
- Cervicovaginal Secretions in Young Women With Bacterial Vaginosis Enhance HIV Infection.The Journal of infectious diseases · 2025Article
- VIRGO2: an enhanced gene catalog of the vaginal microbiome provides insights into its functional and ecology complexity.Nature communications · 2025Article
- Formulation, development and characterization of fosfomycin tromethamine pessaries for the treatment of vaginal infections.Scientific reports · 2025Article
- Innovative vaginal wash formulation with Chitosan nanoparticles targets microbial pathogens, ovarian cancer and inflammation.Scientific reports · 2025Article
- Oral Administration of the ProbioticMicroorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among the infectious causes of vulvovaginal symptoms, bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) dominate. Apart from infrequent mixed infections, both are considered independent and caused by unrelated pathogenic mechanisms. Clinical experience, however, is strongly suggestive that in some populations these infections are linked with recurrent BV (RBV) serving as the dominant etiopathogenic trigger for development of recurrent VVC (RVVC) with profound clinical and therapeutic consequences. The biologic basis for this critical interrelationship is discussed and suggests that as a consequence of BV dysbiosis, and not necessarily because of antibiotics prescribed, immune defenses are compromised, neutralizing vaginal yeast tolerance. The consequent BV-induced vaginal proinflammatory environment predisposes to mixed infection or consecutive episodes of post-treatment VVC. Recurrent BV and repeated antimicrobial drug exposure also predispose to acquired fluconazole resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.